Closing the Gap of Unmet Needs in Inflammatory Pain Management: Case Series of Predimenol for Pain

Rizaldy Pinzon

doi:10.56951/medicinus.v34i2.65

Closing the Gap of Unmet Needs in Inflammatory Pain Management: Case Series of Predimenol for Pain

Penulis

Rizaldy Pinzon Fakultas Kedokteran, Universitas Kristen Duta Wacana/RS Bethesda, Yogyakarta

DOI:

https://doi.org/10.56951/medicinus.v34i2.65

Kata Kunci:

predimenol, inflammation, safety, NSAID, coxib

Abstrak

Chronic inflammatory pain is major medical problem worldwide. Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors are commonly used medications to treat chronic pain. However, these agents have been associated with serious gastrointestinal, renal and cardiovascular adverse effects. This limitation indicates a clear unmet need in terms of safety of current treatment options for the management of chronic inflammatory pain. Those adverse effects may caused by overlapping roles of COX-1 and COX-2 in physiological and pathophysiological processes. Predimenol is a herbal medicine that can be used to treat pain. Recent findings showed that these phytochemicals may directly act upon several inflammatory processes and offer compelling evidence that predimenol could reduce pain and inflammation. We report two cases and short review of the use of predimenol for pain management. Our review showed that predimenol formulations could be a valuable alternative treatment to relieve symptoms of pain with good safety profile. Further researches through large, high quality RCTs to investigate the clinical benefit of predimenol for pain management are needed.

Unduhan

Baca Selengkapnya

Referensi

Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health 2011;11:770. DOI: https://doi.org/10.1186/1471-2458-11-770

May C, Brcic V, Lau B. Characteristics and complexity of chronic pain patients referred to a community-based multidisciplinary chronic pain clinic. Can. J. Pain 2018;2(1):125–34. DOI: https://doi.org/10.1080/24740527.2018.1453751

Sa KN, Moreira L, Baptista AF, et al. Prevalence of chronic pain in developing countries: systematic review and meta-analysis. Pain Rep. 2019;4(6):e779. DOI: https://doi.org/10.1097/PR9.0000000000000779

Dahlhamer J, Lucas J, Zelaya C et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb. Mortal. Wkly. Rep. 2018;67(36):1001–6. DOI: https://doi.org/10.15585/mmwr.mm6736a2

Chen D, Shen J, Zhao W, et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res. 2017;5:16044. DOI: https://doi.org/10.1038/boneres.2016.44

Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–707. DOI: https://doi.org/10.1002/art.34453

Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract: Indigestion and nonsteroidal anti-inflammatory drugs. Br Med J 2001;323(7323):1236–9. DOI: https://doi.org/10.1136/bmj.323.7323.1236

Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am J Kidney Dis 2001;38(6):1145–57. DOI: https://doi.org/10.1053/ajkd.2001.29203

Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002;63(5):817–21. DOI: https://doi.org/10.1016/S0006-2952(02)00842-0

Laufer S. Osteoarthritis therapy—are there still unmet needs? Rheumatology (Oxford) 2004;43(Suppl.1):i9–15. DOI: https://doi.org/10.1093/rheumatology/keh103

Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open 2016;6:e010364. DOI: https://doi.org/10.1136/bmjopen-2015-010364

Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81s-110s. DOI: https://doi.org/10.18433/J3T886

Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;34 (21):1520-8. DOI: https://doi.org/10.1056/NEJM200011233432103

Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord. 2007;8:73. DOI: https://doi.org/10.1186/1471-2474-8-73

Schmidt M, Sorensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ 2018;362:k3426. DOI: https://doi.org/10.1136/bmj.k3426

Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519-29. DOI: https://doi.org/10.1056/NEJMoa1611593

Nelson DA, Marks ES, Deuster PA, O'Connor FG, Kurina LM. Association of Nonsteroidal Anti-inflammatory Drug Prescriptions With Kidney Disease Among Active Young and Middle-aged Adults. JAMA Netw Open. 2019;2(2):e187896. DOI: https://doi.org/10.1001/jamanetworkopen.2018.7896

Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017;18(1):256. DOI: https://doi.org/10.1186/s12882-017-0673-8

Alara OR, Alara JA, Olalere OA. Review on Phaleria macrocarpa Pharmacological and Phytochemical Properties. Drug Des 2016;53):1-5. DOI: https://doi.org/10.1016/j.jarmap.2017.02.002

Hendra R, Ahmad S, Oskoueian E, Sukari A, Shukor MY. Antioxidant, anti-inflammatory and cytotoxicity of Phaleria macrocarpa (Boerl.) Scheff Fruit. BMC Complement Altern Med 2011;11:110. DOI: https://doi.org/10.1186/1472-6882-11-110

Ferraz CR, Carvalho TT, Manchope MF, et al. Therapeutic Potential of Flavonoids in Pain and Inflammation: Mechanisms of Action, Pre-Clinical and Clinical Data, and Pharmaceutical Development. Molecules 2020;25(3):762. DOI: https://doi.org/10.3390/molecules25030762

Tjandrawinata RR, Arifin P, Clarissa A. New concept in the treatment of premenstrual syndrome using bioactive fraction DLBS1442. Medicinus 2011;24(3):21-4.

Tjandrawinata, RR, Nofiarni D, Susanto LW, Hendri P, Clarissa A. Symptomatic treatment of premenstrual syndrome and/or primary dysmenorrhea with DLBS1442, a bioactive extract of Phaleria macrocarpa. Int J Gen Med. 2011;4:465-76. DOI: https://doi.org/10.2147/IJGM.S21053

Wiweko B, Puspita CG, Tjandrawinata R, Situmorang H, Harzif AK, Pratama G, Sumapriya K, Natadisastra M, Hestiantoro A. The effectiveness of Phalleria macrocarpa bioactive fraction in alleviating endometriosis and/or adenomyosis related pain. eJKI 2015;3(1):51–6. DOI: https://doi.org/10.23886/ejki.3.4824.